Masimo expands technology platform for continuous and noninvasive monitoring of carbon monoxide and methemoglobin levels in the blood
Enhanced ability to measure carboxyhemoglobin and methemoglobin allows clinicians to detect and treat potentially life threatening conditions earlier than ever before.
IRVINE, Calif. — Masimo Corporation today announced the expansion of its breakthrough Masimo Rainbow SET Pulse CO-Oximetry platform. In addition to the ability to provide accurate pulse oximetry (SpO2) readings in situations of motion and low perfusion, Masimo Rainbow SET allows clinicians to continuously and noninvasively monitor the level of carboxyhemoglobin (SpCO) and methemoglobin (SpMet) in the blood, helping them detect and treat potentially life threatening conditions earlier than ever before.
The new extensions to the platform include the availability of a bedside monitor, the Masimo Radical-7, which can either be ordered with the ability to monitor SpCO and SpMet direct from the factory, or can be upgraded in the field with the purchase of optional software enhancements at a later date. Additionally, the company is introducing a full line of single-patient adhesive sensors to be able to deliver these enhanced parameters. The new line will include adult, pediatric, infant and neonatal sensors, as well as a ten foot cable.
Carboxyhemoglobin and Methemoglobin are both dysfunctional forms of hemoglobin that are incapable of transporting oxygen, thus reducing blood oxygenation and potentially inducing tissue hypoxemia. Numerous peer-reviewed clinical studies have pointed to the prevalence and significance of these dyshemoglobins, yet because increases in both methemoglobin and carboxyhemoglobin often go undetected until dangerou levels are reached, the rapid diagnosis and treatment of these dyshemoglobins have both quality and cost of care implications.
For more information on Masimo and its breakthrough Rainbow technology, go to www.masimo.com.
The Masimo Radical-7 bedside monitor displaying optional Rainbow parameters-carboxyhemoglobin and methemoglobin-will have received FDA 510k clearance and be available for viewing at the upcoming Annual Meeting of the American Association of Anesthesiologists (ASA) in Chicago from October 14-18.